Association between STAT4 polymorphisms and risk of primary biliary cholangitis: a meta-analysis

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease. Several studies reported that SATA4 (signal transducer and activator of transcription 4) polymorphisms were significantly associated with PBC susceptibility. In order to derive a more comprehensive estimation of the association between STAT4 and PBC risk, this meta-analysis was conducted. Thirteen eligible studies from 8 articles with a total number of 11,310 cases and 27,844 controls were included in this meta-analysis. Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated with fixed effects model or random effects model. The results showed statistically significant association between polymorphisms of rs7574865, rs3024921, rs6752770, rs7601754 and rs10168266 in STAT4 and PBC risk under the allelic effect model (rs7574865, T vs. G, OR = 1.24, 95% CI 1.14–1.35; rs3024921, T vs. A, OR = 1.65, 95% CI 1.44–1.91; rs6752770, G vs. A, OR = 1.24, 95% CI 1.11–1.39; rs7601754, A vs. G, OR = 1.35, 95% CI 1.17–1.55; and rs10168266, T vs. C, OR = 1.31, 95% CI 1.22–1.41). Furthermore, the rs7574865 polymorphism was significantly associated with PBC risk under all genotype genetic models (dominant effect model: TT + TG vs. GG, OR = 1.43, 95% CI 1.19–1.71; recessive effect: TT vs. TG + GG, OR = 1.40, 95% CI 1.24–1.58; and co-dominant effect: TT vs. GG, OR = 1.67, 95% CI 1.37–2.02). The sensitivity analysis by omitting one study at a time showed that the results were stable. No publication bias was indicated from both Begg’s test and Egger’s weighted regression. This meta-analysis suggested that polymorphisms of rs7574865, rs3024921, rs6752770, rs7601754 and rs10168266 in STAT4 were significantly associated with the risk of PBC.